Since PD-1, PD-L1 monotherapy is insufficient and high co-expression of PD-L1 and IDO proteins was described in NSCLC, several clinical trials proposed dual therapy blocking these proteins in NSCLC are ongoing. This evidence concerns the gene IDO1 and non-small cell lung carcinoma.